Allergan: Vraylar Available In U.S. For Bipolar Mania, Schizophrenia Treatment

(RTTNews) - Allergan plc (AGN), said that Vraylar, or cariprazine, a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the U.S.

Vraylar will be commercially available in 30 count bottles in 1.5mg, 3mg, 4.5mg and 6mg, and a 7 count mixed blister pack of one 1.5mg and six 3mg tablets.

Vraylar was approved by the U.S. Food and Drug Administration in September 2015 for the treatment of acute manic or mixed episodes of bipolar I disorder and schizophrenia in adults.

According to Allergan, the safety and efficacy of Vraylar was studied in a clinical trial program which included more than 2,700 adult patients suffering from schizophrenia or bipolar mania.

Bipolar I disorder, also known as manic-depressive illness, and schizophrenia are among the most challenging mental health disorders to manage, and together affect approximately 8.5 million adults in the U.S.

Treatment for both illnesses is often complicated by high rates of relapse and a high degree of variability in disease course and severity, as well as patient symptoms and response to treatment.